From: Tyrosine kinase inhibitor-loaded biomimetic nanoparticles as a treatment for osteosarcoma
Name | Library set | Concentration (mM) | Activity |
---|---|---|---|
Hydroxyurea | NCI Approved Oncology Drug Set V | 10 | RNA inhibitor |
Temozolomide | NCI Approved Oncology Drug Set V | 10 | DNA alkylating agent |
Carmustine | NCI Approved Oncology Drug Set V | 10 | Alkylating agent |
Ifosfamide | NCI Approved Oncology Drug Set V | 10 | Alkylating agent |
Anastrozole | NCI Approved Oncology Drug Set V | 10 | Aromatase inhibitor |
Pipobroman | NCI Approved Oncology Drug Set V | 10 | Alkylating agent |
Axitinib | NCI Approved Oncology Drug Set V | 10 | Tyrosine kinase inhibitor |
Dasatinib | NCI Approved Oncology Drug Set V | 10 | Tyrosine kinase inhibitor |
Vandetanib | NCI Approved Oncology Drug Set V | 10 | Kinase inhibitor |
Ponatinib | NCI Approved Oncology Drug Set V | 10 | RTK inhibitor |
Allopurinol | NCI Approved Oncology Drug Set V | 10 | Purine analog, purine synthesis inhibitor |
Busulfan | NCI Approved Oncology Drug Set V | 10 | DNA alkylating agent |
Cyclophosphamide | NCI Approved Oncology Drug Set V | 10 | Alkylating agent |
Cisplatin | NCI Approved Oncology Drug Set V | 10 | DNA crosslinking agent |
Letrozole | NCI Approved Oncology Drug Set V | 10 | Aromatase inhibitor |
Megestrol acetate | NCI Approved Oncology Drug Set V | 10 | Progestin |
Mitoxantrone | NCI Approved Oncology Drug Set V | 10 | Topo II inhibitor |
Pazopanib hydrochloride | NCI Approved Oncology Drug Set V | 10 | Tyrosine kinase inhibitor |
Vemurafenib | NCI Approved Oncology Drug Set V | 10 | RAF/MEK inhibitor |
Cabozantinib | NCI Approved Oncology Drug Set V | 10 | RTK inhibitor |
Fluorouracil | NCI Approved Oncology Drug Set V | 10 | Thymidylate synthesis inhibitor (antimetabolite) |
Altretamine | NCI Approved Oncology Drug Set V | 10 | Alkylating agent |
Uracil mustard | NCI Approved Oncology Drug Set V | 10 | Alkylating agent |
Tretinoin | NCI Approved Oncology Drug Set V | 10 | ATRA |
Lenalidomide | NCI Approved Oncology Drug Set V | 10 | (Unknown, alter cytokine production) |
Bendamustine hydrochloride | NCI Approved Oncology Drug Set V | 10 | Alkylating agent |
Pemetrexed | NCI Approved Oncology Drug Set V | 10 | Folate antimetabolite |
Imatinib | NCI Approved Oncology Drug Set V | 10 | Tyrosine kinase inhibitor |
Regorafenib | NCI Approved Oncology Drug Set V | 10 | RTK inhibitor |
Bosutinib | NCI Approved Oncology Drug Set V | 10 | RTK inhibitor |
Thiouanine | NCI Approved Oncology Drug Set V | 10 | Purine analog (antimetabolite) |
Floxuridine | NCI Approved Oncology Drug Set V | 10 | Antimetabolite |
Cytarabine hydrochloride | NCI Approved Oncology Drug Set V | 10 | DNA/RNA synthesis inhibitor |
Dexrazoxane | NCI Approved Oncology Drug Set V | 10 | EDTA derivative |
Pomalidomide | NCI Approved Oncology Drug Set V | 10 | Immunomodulator |
Fludarabine phosphate | NCI Approved Oncology Drug Set V | 10 | Purine analog (antimetabolite) |
Gefitinib | NCI Approved Oncology Drug Set V | 10 | EGFR inhibitor |
Sorafenib | NCI Approved Oncology Drug Set V | 10 | Tyrosine-raf- and ser/thr kinase inhibitor |
Idarubicin hydrochloride | NCI Approved Oncology Drug Set V | 10 | Anthracycline |
Daunorubicin hydrochloride | NCI Approved Oncology Drug Set V | 10 | RNA/DNA synthesis inhibitor |
Mercaptopurine | NCI Approved Oncology Drug Set V | 10 | DNA/RNA synthesis inhibitor |
Methoxsalen | NCI Approved Oncology Drug Set V | 10 | Furanocoumarins |
Thalidomide | NCI Approved Oncology Drug Set V | 10 | (unknown, alter cytokine production) |
Pentostatin | NCI Approved Oncology Drug Set V | 10 | Antimetabolite |
Chlorambucil | NCI Approved Oncology Drug Set V | 10 | Alkylating agent |
Bortezomib | NCI Approved Oncology Drug Set V | 10 | Proteasome inhibitor |
Vismodegib | NCI Approved Oncology Drug Set V | 10 | GLI1/GLI2 inhibitors |
Raloxifene | NCI Approved Oncology Drug Set V | 10 | SERM |
Nilotinib | NCI Approved Oncology Drug Set V | 10 | RTK inhibitor |
Doxorubicin hydrochloride | NCI Approved Oncology Drug Set V | 10 | DNA intercalating agent |
Mechlorethamine hydrochloride | NCI Approved Oncology Drug Set V | 10 | DNA alkylating agent |
Lomustine | NCI Approved Oncology Drug Set V | 10 | Alkylating agent |
Procarbazine hydrochloride | NCI Approved Oncology Drug Set V | 10 | Alkylating agent |
Nelarabine | NCI Approved Oncology Drug Set V | 10 | DNA synthesis inhibitor |
Mitomycin | NCI Approved Oncology Drug Set V | 10 | DNA crosslinking agent |
Capecitabine | NCI Approved Oncology Drug Set V | 10 | Pyrimidine analogue |
Crizotinib | NCI Approved Oncology Drug Set V | 10 | Protein kinase inhibitor |
Afatinib | NCI Approved Oncology Drug Set V | 10 | Angiokinase inhibitor |
Ixabepilone | NCI Approved Oncology Drug Set V | 10 | MT stabilizing agent |
Etoposide | NCI Approved Oncology Drug Set V | 10 | Topo inhibitor |
Thiotepa | NCI Approved Oncology Drug Set V | 10 | DNA alkylating agent |
Azacitidine | NCI Approved Oncology Drug Set V | 10 | Inhibitor of DNMTs |
Streptozocin | NCI Approved Oncology Drug Set V | 10 | Alkylating agent |
Vorinostat | NCI Approved Oncology Drug Set V | 10 | HDAC inhibitor |
Mitotane | NCI Approved Oncology Drug Set V | 10 | Unknown (interferes with steroid synthesis) |
Celecoxib | NCI Approved Oncology Drug Set V | 10 | Cox-2 inhibitor |
Methotrexate | NCI Approved Oncology Drug Set V | 10 | Antimetabolite |
Pralatrexate | NCI Approved Oncology Drug Set V | 10 | Antimetabolite |
Romidepsin | NCI Approved Oncology Drug Set V | 10 | HDAC inhibitor |
Tamoxifen citrate | NCI Approved Oncology Drug Set V | 10 | Anti-ER compound |
Aminolevulinic acid hydrochloride | NCI Approved Oncology Drug Set V | 10 | Involved in porphyrin synthesis, used as a photodynamic therapy |
Decitabine | NCI Approved Oncology Drug Set V | 10 | Inhibitor of DNMTs |
Cladribine | NCI Approved Oncology Drug Set V | 10 | Purine analog (DNA synthesis inhibitor) |
Exemestane | NCI Approved Oncology Drug Set V | 10 | Aromatase inhibitor |
Clofarabine | NCI Approved Oncology Drug Set V | 10 | Nucleoside antimetabolite |
Sunitinib | NCI Approved Oncology Drug Set V | 10 | RTK inhibitor |
Topotecan hydrochloride | NCI Approved Oncology Drug Set V | 10 | Topo inhibitor |
Enzalutamide | NCI Approved Oncology Drug Set V | 10 | Androgen receptor inhibitor |
Omacetaxine mepesuccinate | NCI Approved Oncology Drug Set V | 10 | Protein translation inhibitor |
Epirubicin hydrochloride | NCI Approved Oncology Drug Set V | 10 | DNA intercalating agent |
Estramustine phosphate sodium | NCI Approved Oncology Drug Set V | 10 | Depolymerizes MTs, also metabolized to E2 and E1 in the liver |
Carfilzomib | NCI Approved Oncology Drug Set V | 10 | Proteasome inhibitor |
Dactinomycin | NCI Approved Oncology Drug Set V | 10 | RNA PolII inhibitor |
Dacarbazine | NCI Approved Oncology Drug Set V | 10 | Alkylates DNA |
Melphalan hydrochloride | NCI Approved Oncology Drug Set V | 10 | DNA alkylating agent |
Lapatinib | NCI Approved Oncology Drug Set V | 10 | Tyrosine kinase inhibitor |
Docetaxel | NCI Approved Oncology Drug Set V | 10 | Taxane (MT stabilizer) |
Plicamycin | NCI Approved Oncology Drug Set V | 10 | (Mithramycin) RNA synthesis inhibitor |
Arsenic trioxide | NCI Approved Oncology Drug Set V | 10 | APL treatment (in combination with ATRA) |
Abiraterone | NCI Approved Oncology Drug Set V | 10 | CYP17 inhibitor (reduces testosterone levels) |
Irinotecan hydrochloride | NCI Approved Oncology Drug Set V | 10 | Topo I inhibitor |
Cabazitaxel | NCI Approved Oncology Drug Set V | 10 | Taxol derivative |
Bleomycin sulfate | NCI Approved Oncology Drug Set V | 10 | DNA breaks |
Triethylenemelamine | NCI Approved Oncology Drug Set V | 10 | DNA alkylating agent |
Fulvestrant | NCI Approved Oncology Drug Set V | 10 | SERM |
Paclitaxel | NCI Approved Oncology Drug Set V | 10 | MT stabilizer |
Vinorelbine tartrate | NCI Approved Oncology Drug Set V | 10 | MT inhibitor |
Carboplatin | NCI Approved Oncology Drug Set V | 10 | DNA intercalating agent |
Trametinib | NCI Approved Oncology Drug Set V | 10 | MEK inhibitor |
Vinblastine sulfate | NCI Approved Oncology Drug Set V | 10 | MT inhibitor |
Temsirolimus | NCI Approved Oncology Drug Set V | 10 | mTOR inhibitor |
Erlotinib hydrochloride | NCI Approved Oncology Drug Set V | 10 | Tyrosine kinase inhibitor (EGFR specific) |
Dabrafenib mesylate | NCI Approved Oncology Drug Set V | 10 | ATP-competitive kinase inhibitor and targets the MAPK pathway |
Vincristine sulfate | NCI Approved Oncology Drug Set V | 10 | MT disruptor |
Gemcitabine hydrochloride | NCI Approved Oncology Drug Set V | 10 | (Nucleoside analog) inhibits DNA synthesis |
Amifostine | NCI Approved Oncology Drug Set V | 10 | DNA intercalating agent |
Teniposide | NCI Approved Oncology Drug Set V | 10 | Topo II inhibitor |
Sirolimus | NCI Approved Oncology Drug Set V | 10 | (Rapamycin) mTOR inhibitor |
Imiquimod | NCI Approved Oncology Drug Set V | 10 | TLR7 agonist |
Zoledronic acid | NCI Approved Oncology Drug Set V | 10 | Bisphosphonate (prevents bone resorption) |
Valrubicin | NCI Approved Oncology Drug Set V | 10 | Topo II inhibitor |
Everolimus | NCI Approved Oncology Drug Set V | 10 | mTOR inhibitor |
Plerixafor | NCI Approved Oncology Drug Set V | 10 | CXCR4 blocker |
Oxaliplatin | NCI Approved Oncology Drug Set V | 10 | DNA synthesis inhibitor |